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phase. MCD feeding in CRAMP-KO mice led to stronger intra-
hepatic fat accumulation and significantly enhanced matrix 
remodeling, whereas BDL caused more extensive liver ne-
crosis. At the late 28 days time point, MCD-fed CRAMP-KO 
mice displayed a higher intrahepatic fat load. Long-term 
changes in bile-duct-ligated mice included higher collagen 
content as a sign of enhanced fibrosis progression if CRAMP 
was absent.  Conclusion: The study shows a clear correlation 
of antimicrobial peptide serum levels in patients with chron-
ic liver diseases. Furthermore, we were able to demonstrate 
protective functions of LL-37/CRAMP in two independent 
mouse models of chronic liver injury.  © 2015 S. Karger AG, Basel 
 Introduction 
 The innate immune system plays a crucial role during 
the defense against microbes as well as in the initiation of 
the inflammatory response. Here, antimicrobial peptides 
(AMPs) serve as an evolutionary well-conserved and im-
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 Abstract 
 Background: Antimicrobial peptides (AMP) are an impor-
tant defense mechanism of the innate immune system and 
can modulate the course of various diseases. However, their 
significance during liver pathogenesis is currently not well 
defined.  Methods: Patients with liver diseases were analyzed 
for LL-37/CRAMP, human beta-defensin-2 (hBD2), and com-
plement 5a (C5a) serum levels. Mice deficient in CRAMP (Cat-
helicidin-related Antimicrobial Peptide), the mouse homo-
log for human LL-37, were fed with a methionine- and cho-
line-deficient diet (MCD) and underwent bile-duct ligation 
(BDL).  Results: First, serum samples from patients with 
chronic liver diseases were investigated. Therefore, signifi-
cantly enhanced levels for LL-37, hBD2, and complement 
C5a were detected, all of which comprise antimicrobial 
properties. Next, CRAMP-knockout (CRAMP-KO) mice were 
investigated, to better define a functional role of LL-37/
CRAMP in animal models of liver diseases. MCD feeding and 
bile-duct ligation of CRAMP-KO mice resulted in an en-
hanced degree of liver injury during the early treatment 
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portant defense mechanism against bacteria and fungi in 
eukaryotic organisms. AMPs are usually produced and 
secreted by epithelial cells and lymphocytes, mainly gran-
ulocytes  [1] .
 LL-37, the human homolog of the cathelicidin-related 
antimicrobial peptide (CRAMP), is the sole member of 
the human cathelicidin family. Its biologic function is pri-
marily the initiation of bacterial lysis through the forma-
tion of wall pores in prokaryotes. Besides its direct anti-
microbial function, it also has so far not yet thoroughly 
defined immune modulatory functions. The peptide 
comprises both pro- and anti-inflammatory properties 
that are modulated by the tissue environment and spe-
cific diseases  [2] . Its proinflammatory phenotype be-
comes evident during monocyte differentiation, where it 
can drive cell plasticity toward M1 macrophage differen-
tiation and IL-10 downregulation  [3] . There is also a 
strong anti-inflammatory function through a modulation 
of TLR signaling described  [4] . By downregulating the 
LPS-driven TLR4 response, it can thus prevent macro-
phage activation and the production of proinflammatory 
cytokines  [5] . Its expression is regulated through inflam-
matory signaling  [6] , the vitamin-D pathway  [7], and en-
doplasmatic reticulum stress  [8] . Previous experiments 
using mice deficient in the murine ortholog CRAMP have 
demonstrated the importance of this peptide during the 
antimicrobial defense and inflammation  [9, 10] . Thus, it 
was shown that LL-37/CRAMP is required to prevent 
bacterial infections in the skin, the colon, and the urinary 
tract. Moreover, we have recently demonstrated further 
antimicrobial functions of the peptide in rodent models 
of meningitis and cerebral infection  [11, 12] .
 With regard to the liver, it is known that activation of 
toll-like receptor (TLR) signaling – mostly through patho-
gen-associated molecular pattern molecules (PAMP) – is 
one of the major inflammatory pathways that promote 
progression of chronic hepatic diseases  [13] . This is evi-
dent for both metabolic and cholestatic diseases, which 
ultimately result in the development of fibrosis and organ 
insufficiency. Here, bacterial toxins from the gut sustain 
an inflammatory response, which contributes to hepatic 
kupffer cell activation, promotes stellate cells to myofibro-
blast differentiation and the subsequent production of ex-
tracellular matrix as the morphologic correlate of fibrosis. 
Experiments in TLR4-deficient mice demonstrated that 
targeted disruption of this signaling pathway can effi-
ciently prevent the development of hepatic fibrosis in the 
cholestatic mouse model of bile-duct ligation  [14] .
 Within this study, we first aimed at correlating AMP 
serum level with the presence of liver diseases. This might 
be helpful to better define patients’ prognosis or response 
to therapies. To more thoroughly define a functional role 
for AMPs during the course of liver diseases, as suggested 
in our own previous study  [15], we applied CRAMP-de-
ficient (KO) mice to respective animal models. Especially 
models of metabolic and cholestatic injury are of interest, 
as here relevance for an involvement of AMPs due to a 
disturbed gut-liver axis is likely.
 Materials and Methods 
 Ethical Statement 
 This study was carried out in strict accordance with the rec-
ommendations of the Ethics of the regional authorities for na-
ture, environmental and consumer protection of North Rhine-
Westfalia (LANUV – Landesamt für Natur, Umwelt und Verbr-
aucherschutz NRW) Recklinghausen, Germany, and approved 
by the LANUV Committee (Permit Number: TV10695G1). All 
surgeries were performed under ketamin-hydrochloride/xyl-
azin-hydrochloride anesthesia, and all efforts were made to min-
imize suffering.
 Housing and Generation of Mice 
 Both CRAMP knockout  [16] and the corresponding wild-
type (WT) mice were used as experimental animals in a C57BL/6 
background. At least five mice per group were treated and ana-
lyzed in parallel for all experiments, which were repeated at least 
twice. Mice were housed in 12 h light/dark cycles with water and 
food freely available in the animal facility of the University Hos-
pital RWTH Aachen, and were treated in accordance with the 
criteria of the German administrative panel on laboratory animal 
care.
 Bile-Duct Ligation/MCD Treatment 
 Eight- to ten-week-old mice were subjected to bile-duct liga-
tion (BDL) as indicated. BDL was performed in anesthetized mice 
by tying the common bile duct using a non-absorbable filament 
(Ethicon, Boston, Mass., USA). For each of the following analysis, 
at least 5 mice per genotype and time point were investigated. All 
experiments were performed at least twice.
 For dietary treatment, 8 – 12-week-old male mice weighting 
25  g were fed either a methionine- and choline-deficient diet 
(MCD) or a chow diet (MP Biomedicals, LLC, Ohio, USA). Both 
knockout and wild-type animals showed a food intake of 56 g per 
day without differences between chow and dietary treatment.
 Blood Collection 
 For retro-orbital bleeding, mice were briefly anesthetized with 
isoflurane and blood was collected via a glass capillary. Samples 
were centrifuged at 10,000 rpm for 10 min, aliquoted and serum 
was stored at –80  °  C until further analysis.
 Histology, Sirius-Red, and Oil-Red Staining 
 Liver samples were either snap frozen in OCT compound or 
fixed in 4% formaldehyde, embedded in paraffin, cut, and stained 
with hematoxylin and eosin. Pictures were taken using an Axio-
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genotype. For Sirius-red staining, the paraffin sections were incu-
bated in the Sirius-red-staining solution (Polysciences Inc., 55780, 
Eppelheim,  Germany) for 1 h. Thereafter, the slides were incu-
bated in 0.1  M HCl for 5 min, treated with an ascending ethanol 
series, incubated in Roti-Histol (Roth, Karlsruhe, Germany), and 
finally covered with Roti-Histokit (Roth, Karlsruhe, Germany). 
The sections were analyzed under polarized light. Photomicro-
graphs of Sirius-red positive areas taken in a 10× magnification 
were analyzed via color error measurement using the open source 
software ImageJ. Then, collagen filaments were morphometrically 
analyzed and used for the calculation of collagen per area field. For 
oil-red staining, frozen sections were fixed in formalin, washed in 
PBS, and then stained with Oil-red-O staining solution (Sigma, 
Steindorf,  Germany). After rinsing with water, nuclei were stained 
with hematoxylin.
 Immunofluorescence Stainings 
 Liver cryosections (5 μm) were air-dried and fixed with ice-
cold acetone. After rehydration in phosphate-buffered saline 
(PBS), the samples were treated with 2 N HCl for 30 min and af-
terward neutralized with 0.1  M sodium borate (pH 8.0) for 9 min. 
The samples were washed in PBS. Antibodies were incubated in 
0.2% bovine serum albumin (BSA) and 10% goat serum in PBS 
(anti-BrdU: 1: 40; Becton Dickinson, Heidelberg, Germany) for 1 h 
at 37  °  C or overnight at 4  °  C, respectively. For the detection of col-
lagen tissue, sections were fixed in 4% PFA (Roth, Karlsruhe, 
 Germany) and blocked in 2% BSA in PBS acid. Incubation of the 
first antibody was performed overnight at 4  °  C or 1 h at room tem-
perature, respectively (anti-collagen type 1: 1: 250; Biotrend, Co-
logne, Germany; anti-Ki67: 1: 100 in 0.3% Triton X-100, 5% goat 
serum in PBS; Nova Castra Laboratories, Newcastle upon Tyne, 
UK). After washing in PBS, Alexa Fluor 488 and/or 594-conju-
gated secondary antibodies (Molecular Probes/Invitrogen, Karl-
sruhe, Germany) were used for immunofluorescence detection. 
The sections were analyzed using a fluorescence microscope 
(Zeiss, Jena, Germany).
 Patient Collection and Statistics 
 Serum samples of 30 patients without liver disease and of 80 
patients with liver disease were collected in the Department of Gas-
troenterology, RWTH University Hospital Aachen, Germany. The 
local ethics committee approved the study protocol. Written in-
formed consent was obtained from the patient, his or her spouse, 
or the appointed legal guardian. Levels of antimicrobial peptides 
human beta-Defensin-2, C5a, and LL37 were determined by 
 ELISA as described next. Significances were analyzed by unpaired 
Student’s t test and are indicated by  * ( *  p < 0.05).
 ELISA 
 Patient blood samples were prepared according to the instruc-
tions of the manufacturer of the ELISA kits after blood withdrawal 
and stored at –80  °  C until further analysis. Importantly, serum sam-
ples were centrifuged twice to ensure any contamination of neutro-
phils and blood cellular material, which lead to false positive AMP 
values. All samples were run in duplicate to ensure result consisten-
cy. If values differed >15%, the particular sample was re-analyzed.
 For serum analysis, we used the following assays: LL37, human, 
ELISA (Cat.# HK321–02, Fa: Hycultec GmbH, Beutelsbach, 
 Germany), human beta defensin-2, (human BD-2, Cat. No. 
K0331208, Fa: Komabiotech, Yangpyeong-dong, Korea), and Hu-
man Complement Component C5a Duo Set (Cat. No. DY2037, Fa: 
R&D Systems, Wiesbaden-Nordenstadt, Germany).
 After applying the substrate 3,3 ′ ,5,5 ′ -tetramethylbenzidine-di-
hydrochloride (Sigma-Aldrich, Steinheim, Germany) and termi-
nation of the substrate reaction with sulfuric acid, the absorbance 
was measured in a fluorescent plate reader at a wavelength of 
450 nm. The absorbance values were converted to μg/ml by com-
parison with a standard curve according to the instructions of the 
manufacturer.
 TUNEL Assay 
 Cryosections (5 μm) were air-dried and fixed with 4% parafor-
maldehyde at room temperature. After washing with PBS, the 
slides were incubated for 10 min in 3% H 2 O 2 methanol followed 
by a 2-min incubation in sodium citrate (0.1%). After washing in 
PBS, the substrate mixture was applied according to the manufac-
turer’s instructions (Roche, Mannheim, Germany).
 Quantification and Statistics 
 All numerical results are expressed as mean ± SEM and repre-
sent data from at least four animals per time point. Calculations 
via manual counting of positive cells were done with five to 10 high 
power fields/liver. All significant p values were measured by the 
Student’s t test. A value of p < 0.05 was considered significant ( *  p < 
0.05,  * *  p < 0.01,  * * *  p < 0.001).
 Results 
 Antimicrobial Peptides Are Positively Correlated with 
Chronic Liver Disease 
 In order to analyze the importance of antimicrobial 
peptides during the development of chronic liver disease, 
we determined patient serum levels of two different anti-
microbial peptides (AMPs: human beta-Defensin 2 
(hBD2) and LL-37). In addition, we analyzed serum levels 
of complement 5a (C5a), an important activator of the 
complement cascade, being also involved in bacterial ly-
ses, inflammation, and chemotaxis and thus closely re-
lated to the function of AMPs. Serum samples of 30 pa-
tients without liver disease were compared with serum 
samples of 80 patients with chronic liver disease. Our 
analysis showed that patients with existing chronic liver 
disease displayed significantly elevated serum levels of 
hBD2, C5a, and LL-37 ( fig. 1 a–c). A further analysis of 
patients with various underlying liver disease entities un-
raveled that LL-37 serum levels during ethanol-induced 
injury, HVC, NASH, and cryptogenic liver diseases were 
significantly different from control patients (determined 
by unpaired Student’s t test). Statistical significance could 
not be shown for patients with HBV and PBC/PSC, al-
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 CRAMP-KO Mice Show an Enhanced Liver Fat 
Accumulation after MCD Treatment 
 To verify the significance of increased serum level of 
AMPs (especially of LL-37) and C5a in patients with liver 
diseases, mice deficient for CRAMP (CRAMP-KO) – the 
mouse homolog of the human cathelicidin LL-37 – were 
applied to two different and widely used models of chron-
ic liver injury: methionine/choline-deficient (MCD) diet 
and bile-duct ligation (BDL). The pathogenesis of both 
mouse models was shown to be related to gut-derived bac-
teria mediated by hepatopetal portal blood flow  [14, 17, 18] 
and can therefore be used as a tool to better understand the 
functional role of AMPs during liver pathogenesis.
 CRAMP-KO mice were first treated with MCD diet 
for 7 days and 28 days to investigate the impact of LL-
37/CRAMP on the course of metabolic liver injury. Se-
rum analysis after 7 days displayed a significantly in-
creased ALT level in CRAMP-KO animals ( fig. 2 a), thus 
indicating a greater degree of liver injury within this 























































































































































 Fig. 1. Serum level of beta-defensin 2, C5a, and LL-37 peptides in 
human samples. Serum expression levels of antimicrobial peptides 
beta-defensin 2 ( a ), C5a ( b ), and LL-37 ( c ) were determined by 
ELISA. Therefore, serum samples of healthy individuals were com-
pared with serum samples of patients with liver disease ( a ,  b – 42 
patients). LL-37 serum samples (80 patients) were further grouped 
for different underlying liver disease entities ( d–i ). Displayed are 
the sub-analyses for ethanol-induced injury, NASH, HBC, HCV, 
cryptogenic liver diseases, and PBC/PSC. Error bars represent 
mean values with standard deviation. Significances were deter-
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 Fig. 2.  a Enhanced hepatic fat accumulation after MCD treatment. 
Displayed are serum alanine aminotransferase (ALT) levels of WT 
and CRAMP-KO mice 0d and after 7 days of feeding a methionine-
choline deficient diet (7 days MCD). Values are means ± SEM. 
 *  p < 0.05).  b Representative images of H&E-stained histological 
slides of WT and CRAMP-KO animals (untreated and MCD fed 
for 7 days, 40× magnification).  c Displayed are Oil-Red-O -stained 
liver sections from WT and CRAMP-KO animals (untreated and 
after 7 days of MCD feeding, 7 days MCD) showing the progressive 
increase of Oil-Red-O staining in CRAMP-KO mice after MCD 
feeding (40× magnification).  d ,  e Depicted are representative im-
ages and a quantitative analysis of Sirius-red staining showing the 
beginning of fibrosis in CRAMP-KO animals after 7 days of MCD 
feeding (7 days MCD) in comparison to MCD-fed wild type and 
to untreated controls (magnification of ×40.  * * *  p < 0,001).  f Dis-
played are hydroxyproline levels of untreated WT and CRAMP-
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(For figure see next page.)
vealed the appearance of more ballooned hepatocytes 
and lipid droplets within their livers (data are displayed 
as H&E and Oil-red-O staining;  fig. 2 b, c). There was 
also a tendency toward an earlier and stronger accumu-
lation of extracellular matrix ( fig. 2 d–f) in CRAMP-KO 
animals.
 Analysis of the 28d time point during MCD feeding 
showed a further progressive accumulation of hepatic 
fat in CRAMP-KO mice, although the elevated trans-
aminases were not significantly different between sub-
groups anymore ( fig. 3 a). However, at this time point, 
still increasing fatty liver degeneration ( fig. 3 b) in mice 
lacking CRAMP could be related to extracellular matrix 
accumulation in both groups of animals ( fig.  3 c–e). 
Those findings were confirmed by subsequently per-
formed Oil-red-O stainings ( fig. 3 f). Biochemical quan-
tification brought further evidence for a clearly en-
hanced hepatic triglyceride accumulation ( fig.  3 g) in 
CRAMP-KO mice.
 BDL Leads to Enhanced Liver Fibrosis Progression in 
CRAMP-KO Mice 
 Next, we applied WT and CRAMP-KO mice to bile-
duct ligation. This model shows the clearest link to an in-
volvement of intestinal bacterial translocation  [14] as a 
contributor for liver pathogenesis. CRAMP-KO mice dis-
played enhanced serum ALT level after 7 days of BDL 
( fig. 4 a). Morphometric analysis of livers from bile-duct-
ligated CRAMP-KO mice and their respective controls 
then unraveled more liver tissue remodeling ( fig.  4 b). 
Here, livers of CRAMP-KO mice showed more and larger 
necrotic areas covering the analyzed liver tissue. Interest-
ingly, we observed a significant enhanced cell prolifera-
tion ( fig. 4 c) within the same group. TUNEL analysis un-
dertaken to detect apoptotic cells within the hepatic tissue, 
however, did not show differences between both groups 
( fig. 4 d).
 To determine whether these early changes would result 
in long-term differences within the hepatic tissue archi-
tecture, WT and CRAMP-KO mice were further analyzed 
28d after bile-duct ligation. Transaminases were elevated 
in both groups ( fig. 5 a). Interestingly, histomorphological 
analysis then unraveled a significantly stronger liver re-
modeling and extracellular matrix accumulation in mice 
lacking CRAMP ( fig. 5 b). This became evident by more 
bridging fibrosis and an enhanced Sirius-red staining 
( fig. 5 c). By collagen immunofluorescence and the use of 
a hydroxyproline assay ( fig. 5 d, e), we were able to bio-
chemically confirm the increased hepatic collagen con-
tent in CRAMP-KO mice.
 Discussion 
 There is compelling evidence coming from numerous 
human and rodent animal model studies for the impor-
tance of defensins and microbial peptides during the in-
nate phase of immune response. The most evidence for 
their disease-modifying role comes from studies in hu-
man subjects of the respiratory tract, the skin, as well as 
from those with inflammatory bowel disease and diar-
rhea. In general, defensins and AMPs such as LL-37 have 
two major functions in host defence: direct inhibition of 
pathogens and modulation of other innate and adaptive 
immune responses  [19] . However, data about their in-
volvement during the progression of liver diseases are 
rare. Our results now show a positive correlation between 
liver diseases in general and serum levels of hBD2, LL-37, 
and the complement factor C5a. Interestingly, serum lev-
els of all three parameters were within a narrow range in 
control patients, but quite differently elevated in patients 
with liver diseases. Some patients showed only minor 
changes, whereas others displayed a largely induced level, 
thus reflecting a broad variability in AMP serum level. 
 Fig. 3. Long-term changes after MCD treatment.  a Displayed are 
serum alanine aminotransferase (ALT) levels of WT and CRAMP-
KO mice at 0 days and after 28 day of feeding a methionine-choline 
deficient diet (28 days MCD).  b Exhibited are representative im-
ages of H&E-stained histological slides of WT and CRAMP-KO 
animals (0 days MCD control and 28 days MCD) at a magnifica-
tion of 40×. Treated CRAMP-KO animals show a stronger pro-
gressing steatosis in comparison to fed WT mice.  c ,  d Representa-
tive images and a quantitative analysis of Sirius-red staining show 
the enhanced fibrosis progression in CRAMP-KO animals after 28 
days of MCD feeding (28 days MCD) in comparison to the fed 
wild-type and to untreated controls (0 days MCD) at a magnifica-
tion of 40×.  e Shown are hydroxyproline levels of untreated WT 
and CRAMP-KO mice (0 days MCD) and 28 days after MCD feed-
ing (28 days MCD).  f Microscopy of Oil-red-O stained liver sec-
tions from WT and CRAMP-KO animals (untreated 0 day MCD 
and after 28 days of MCD feeding, 28 days MCD) showing the 
progressive increase of Oil-red-O staining in WT and CRAMP-
KO mice after MCD feeding with an even more Oil-red-O positive 
area in the CRAMP-KO at a (40× magnification).  g Displayed are 
hepatic triglyceride levels of WT and CRAMP-KO mice 28 days 
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Therefore, most liver disease entities displayed a signifi-
cantly elevated LL-37 serum level, as shown for ethanol-
induced injury, NASH, HCV, and cryptogenic liver dis-
eases. HBV and PBC/PSC patients, however, showed a 
clearly elevated LL-37 level, although not reaching the 
level of significance. Further clear correlations with dis-
ease progression (child status, bilirubin level, etc.) could 
not be demonstrated (data not shown).
 Since CRAMP-KO mice  [16] are available, a growing 
body of data is being generated, which illustrates its func-
tion in mouse models of various diseases. Most of the cur-
rent knowledge comes from lung injury models, where 
murine CRAMP can act both anti- and proinflammatory 
 [20] . Thus, its role during the chemotactic recruitment of 
neutrophils remains two sided. Interestingly, under some 
conditions – such as self-limiting respiratory diseases – 
large numbers of neutrophils can be recruited, which can 
release enormous amounts of AMP.
 One can imagine that the first, rather proinflamma-
tory step might help at the end to combat the infection. 
Interestingly, LL-37 can also interfere with apoptosis in-
duction in neutrophils through a formyl peptide recep-
tor-mediated mechanism that was accompanied with the 
phosphorylation of ERK-1/2, expression of Bcl-x(L) (an 
antiapoptotic protein), and inhibition of caspase-3 activ-
ity. This suppression of neutrophil apoptosis then results 
 Fig. 4. Inflammation and regeneration of hepatic tissue after BDL, 
 a Displayed are serum alanine aminotransferase (ALT) levels of 
WT and CRAMP-KO mice untreated (0 days BDL) and 7 days af-
ter bile-duct ligation (7 days BDL).  b Representative images of 
H&E-stained histological slides of WT and CRAMP KO animals 
(untreated and 7 days after BDL) are shown at a magnification of 
10×.  c Presented are Ki67-positive cells per visual field of WT and 
CRAMP-KO mice (untreated (0 days BDL) and 7 days after bile-
duct ligation (7 days BDL) ( * *  p < 0.01)).  d Shown are TUNEL-
positive cells per visual field of WT and CRAMP-KO mice un-
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 Fig. 5. Long-term changes after BDL.  a Displayed are serum ala-
nine aminotransferase (ALT) levels of WT and CRAMP-KO mice 
untreated (0 days BDL) and 28 days after bile-duct ligation (28 
days BDL).  b Representative images of H&E-stained histological 
slides of WT and CRAMP-KO animals (untreated and 7 days after 
BDL) are shown at a magnification of 10×. Livers of CRAMP-KO 
mice show more liver damage (necrosis and bile-duct infarcts) 
over time.  c  Representative images of Sirius-red staining display an 
enhanced fibrosis progression in CRAMP-KO animals after 28 
days of BDL (28 days BDL) in comparison to bile-duct-ligated WT 
mice and to untreated controls (0 days BDL) at a magnification of 
5×.  d Depicted are images of collagen immunohistochemical stain-
ing at a magnification of 5x, indicating that fibrosis in CRAMP-KO 
mice at 28 days after BDL is increased compared with WT mice at 
28 days after BDL and untreated controls (0 days BDL).  e Shown 
are hydroxyproline levels of WT and CRAMP-KO mice untreated 
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in the prolongation of their lifespan and may be advanta-
geous for host defense against bacterial invasion  [21] .
 Our subsequently performed animal experiments 
showed that the lack of CRAMP in mice renders them, in 
general, more susceptible for liver injury. Although we 
used a metabolic and a cholestatic model, the observed 
liver injury patterns in CRAMP-KO mice were similar. 
Within the MCD model, the predominant phenotype was 
fatty degeneration, whereas BDL provoked more matrix 
accumulation, resulting in a stronger onset of liver fibro-
sis if CRAMP was absent. Cell-protective effects of LL-37/
CRAMP have long been described  [22] . Potential under-
lying mechanisms were mostly characterized with regard 
to pathogen clearance on a cellular level using tissue cul-
ture experiments. Observed effects in hepatic injury mod-
els, however, can be better explained by more indirect, 
anti-inflammatory functions of the peptide. Of special in-
terest here is the interference of LL-37 with the LPS-sig-
naling pathway. In epithelial cell lines, it was shown that 
LPS/cyclohexemide-induced cell death could be inhibit-
ed through LL-37 stimulation. This interaction most like-
ly happens at the level of the CD14/TLR4 interaction, al-
though questions still remain here. Through this inhibi-
tion, TLR4-induced JNK activation and apoptotic 
signaling can be inhibited  [23] . An interaction with the 
TLR4 pathways becomes of special interest, when one 
takes into account that mice deficient in TLR4 signaling 
are protected against BDL  [14] or MCD-induced liver in-
jury  [18] . Under both conditions in TLR4-KO mice as 
well as after gut sterilization, liver fibrosis development 
was largely attenuated.
 Several mouse homologs for human beta defensins, 
another class of AMPs involved in the regulation of the 
innate immune response, have been found. However, the 
general role of defensins and other AMP homologs in 
mice is not fully understood. Human-beta defensine-1 
KO mice showed a slower clearance of bacterial species 
during lung injury but no obvious phenotype with regard 
to their inflammatory response  [24] . Thus, one has to 
consider that different defensins might rather act coop-
eratively together and that therefore the deletion of indi-
vidual members is rather uncritical, as one might be able 
to compensate for another. Especially human beta defen-
sins 2 – 4 are expressed during infectious or inflammatory 
stimuli and thus serve as important co-defenders against 
microbial components and immune regulators. Our find-
ings can complete earlier data on hBD2 expression during 
cholangitis  [25] , where it was shown that especially hBD2 
was expressed in cells of the biliary epithelium. However, 
it remains elusive as to whether our correlation of hBD2 
expression in sera of patients with hepatic diseases might 
reflect an increased remodeling of biliary epithelia, which 
occurs during the development of liver diseases. Comple-
ment 5a (C5a), which is also known as a critical modula-
tor of liver immunity, was found to be increased in pa-
tients with liver diseases as well. It was previously shown 
that it was increased in hepatitis B patients  [26] . The au-
thors showed that C5a could activate hepatic stellate cells 
and stimulate matrix production. Another work by Hill-
ebrandt et al.  [27] identified C5a as an important quanti-
tative trait gene that was associated with advanced liver 
fibrosis.
 Our study now shows for the first time a positive cor-
relation of antimicrobial peptide serum levels with the 
presence of liver disease. This became true for different 
liver disease entities, as from viral hepatitis (HCV) to 
NASH clearly  enhanced LL-37 could be detected. We 
therefore think that the release of AMPs during liver dis-
ease represents a rather general and not a disease-specific 
mechanism. To determine whether this finding reflects a 
reaction against enhanced bacterial translocation in the 
gut or an unspecific inflammatory response remains to be 
determined through future investigations. Mouse animal 
data further suggest a protective role of LL-37/CRAMP, 
particular during hepatic fatty liver degeneration and/or 
fibrosis development in mice (bile-duct ligation model), 
both of which are conditions that also develop in humans 
as a general response to chronic hepatic injury. However, 
further research is needed to fully understand the exact 
role of LL-37/CRAMP and other individual AMPs in in-
nate immune response during the pathogenesis of liver 
diseases. This will help to better explore their potential for 
prognostic or even therapeutic uses.
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